Sandbox g44: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
{{Pathogen|Mycoplasma genitalium}} | {{Pathogen|Mycoplasma genitalium}} | ||
:* Urethritis and cervicitis<ref>{{Cite journal| issn = 1545-8601| volume = 64| issue = RR-03| pages = 1–137| last1 = Workowski| first1 = Kimberly A.| last2 = Bolan| first2 = Gail A.| title = Sexually transmitted diseases treatment guidelines, 2015| journal = MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control| date = 2015-06-05| pmid = 26042815}}</ref> | :* '''1. Urethritis and cervicitis'''<ref>{{Cite journal| issn = 1545-8601| volume = 64| issue = RR-03| pages = 1–137| last1 = Workowski| first1 = Kimberly A.| last2 = Bolan| first2 = Gail A.| title = Sexually transmitted diseases treatment guidelines, 2015| journal = MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control| date = 2015-06-05| pmid = 26042815}}</ref> | ||
::* Preferred regimen (macrolide-susceptible strains): [[Azithromycin]] 1 g PO as a single dose {{or}} [[Azithromycin]] 500 mg PO as a dose followed by 250 mg PO qd for 4 days | ::* Preferred regimen (macrolide-susceptible strains): [[Azithromycin]] 1 g PO as a single dose {{or}} [[Azithromycin]] 500 mg PO as a dose followed by 250 mg PO qd for 4 days | ||
::* Preferred regimen (for patients with previous treatment failures): [[Moxifloxacin]] 400 mg PO qd for 7–14 days | ::* Preferred regimen (for patients with previous treatment failures): [[Moxifloxacin]] 400 mg PO qd for 7–14 days | ||
:* '''2. Pelvic inflammatory disease (PID)'''<ref>{{Cite journal| issn = 1545-8601| volume = 64| issue = RR-03| pages = 1–137| last1 = Workowski| first1 = Kimberly A.| last2 = Bolan| first2 = Gail A.| title = Sexually transmitted diseases treatment guidelines, 2015| journal = MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control| date = 2015-06-05| pmid = 26042815}}</ref> | |||
::* Preferred regimen: [[Moxifloxacin]] 400 mg PO qd for 14 days | |||
Revision as of 17:36, 1 July 2015
- 1. Urethritis and cervicitis[1]
- Preferred regimen (macrolide-susceptible strains): Azithromycin 1 g PO as a single dose OR Azithromycin 500 mg PO as a dose followed by 250 mg PO qd for 4 days
- Preferred regimen (for patients with previous treatment failures): Moxifloxacin 400 mg PO qd for 7–14 days
- 2. Pelvic inflammatory disease (PID)[2]
- Preferred regimen: Moxifloxacin 400 mg PO qd for 14 days
- ↑ Workowski, Kimberly A.; Bolan, Gail A. (2015-06-05). "Sexually transmitted diseases treatment guidelines, 2015". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 64 (RR-03): 1–137. ISSN 1545-8601. PMID 26042815.
- ↑ Workowski, Kimberly A.; Bolan, Gail A. (2015-06-05). "Sexually transmitted diseases treatment guidelines, 2015". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 64 (RR-03): 1–137. ISSN 1545-8601. PMID 26042815.